Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B Study of PTC596 in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma

Trial Profile

A Phase 1B Study of PTC596 in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dacarbazine (Primary) ; PTC 596 (Primary)
  • Indications Leiomyosarcoma
  • Focus Adverse reactions
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 06 Sep 2019 Planned End Date changed from 16 Dec 2020 to 20 Dec 2020.
    • 06 Sep 2019 Planned primary completion date changed from 16 Dec 2020 to 20 Dec 2020.
    • 02 May 2019 According to a PTC Therapeutics media release, the company expects to fully enroll in this study by the end of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top